The purpose of this study is to assess the safety, tolerability, and antitumor activity, as well as recommended dose of brentuximab vedotin in combination with a multiagent chemotherapy regimen.
A retrospective study sought to determine the risk factors for thromboembolism in patients with acute leukemia or lymphoma.
Strong positive association noted, with incidence increasing in BMIs greater than 24.2 kg/m².
Survival benefit seen for radiotherapy after ABVD regimen, but difference not statistically significant.
Prevalence higher for advanced adenomas, advanced serrated lesions, serrated polyposis syndrome.
Researchers present results of an interim analysis of a study on the prevalence of advanced colorectal neoplasia among survivors of Hodgkin lymphoma.
A retrospective evaluation of patients treated at a tertiary cancer center demonstrated that patients with Hodgkin lymphoma experienced periods of actionable distress in survivorship, despite a low overall distress burden.
Although brentuximab vedotin offers clinical benefit over bleomycin in first-line treatment of adults with advanced Hodgkin lymphoma, investigators find the drug is not cost-effective.
A substudy of a multinational study sought to determine the risk to ovarian function with ABVD, AVD, and BEACOPP regimens on ovarian function in women with Hodgkin lymphoma.
A retrospective study evaluated the efficacy vs pulmonary toxicity of brentuximab vedotin for relapsed or refractory Hodgkin lymphoma in pediatric patients.
